Report: Science over Stigma: The Public Health Case Against HCV Treatment Sobriety Restrictions

Sep 14, 2017 | Kim Rodgers

In response to the introduction of effective, short-course, curative hepatitis C (HCV) treatments, shifting HCV trends nationwide, and calls for universal access to treatment, NASTAD has recently released Science over Stigma: The Public Health Case Against HCV Treatment Sobriety Restrictions,which explores the impact of private and public insurance sobriety requirements that are barriers to HCV treatment.

Science over Stigma highlights the discriminatory, biased, and unnecessary practice of requiring a period of sobriety prior to receiving HCV curative treatment. HCV kills more people than all other 60 infectious diseases tracked by the Centers for Disease Control and Prevention (CDC) combined. Among people who inject drugs (PWID), the prevalence of HCV is a staggering 70% and while clinical recommendations suggest that everyone diagnosed should receive curative treatment, only a fraction of these individuals are currently eligible due to onerous and discriminatory sobriety restrictions. To achieve the goal of ending the HCV epidemic, stop the spread of the disease, and improve community health outcomes, it’s critical to reverse these devastating policies.

Key findings of the report include:

  1. People who use drugs can adhere to treatment – Eligibility protocols based on sobriety are based on outdated, biased assumptions about the ability of people who use drugs to adhere to complex medical regimens. This assumption has been discredited by an Australian HCV study that indicated a similar adherence rate between drug users and non-drug users alike.
  2. Risk of re-infection among PWID is minimal – Several studies have shown that the risk of reinfection is low, especially when coupling HCV treatment with other harm reduction interventions such as medication-assisted treatment and syringe services programs (SSPs).
  3. Offering HCV curative treatment reduces the amount of transmissible disease within communities most affected – By increasing testing, treatment, and coordinated linkage to care, HCV prevalence will be reduced within communities at high-risk of exposure to the virus such as PWID. Offering this care in conjunction with SSPs reduces HCV, HBV and HIV risk.
  4. Treatment of HCV among PWID is cost-effective and demonstrates the need for accessible, equitable insurance for all – The cumulative cost of treating HCV in America is estimated at $6.5 billion currently and projections will peak in 2024 at $9.1 billion. Prevention through SSPs and curative treatment is far less costly than the overall burden of untreated chronic care for people living with HCV.

NASTAD envisions a time when new HCV infections in the United States are rare, and when they do occur, every person, regardless of substance use status, age, gender, race/ethnicity, sexual orientation, gender identity, disability, socio-economic status, incarceration status or geographic location, will have access to quality, affordable health care including comprehensive screening, care, and treatment leading to cure, without stigma and discrimination.

For more information on NASTAD’s document Science over Stigma, their hepatitis or drug user health programs and policy activities, please contact Chris Taylor, Senior Director, Hepatitis or Laura Pegram, Manager, Drug User Health.


About Kim Rodgers

Pronouns: She/Her

Kim Rodgers was formerly the Communications Manager at NACCHO.

More posts by Kim Rodgers

Related Posts

D4 web

Day Four Highlights: 2024 Preparedness Summit

See highlights from the final day of the 2024 Preparedness Summit.

Mar 28, 2024

Day Four Highlights: 2024 Preparedness Summit

I Stock 1182682774
  • Adverse Childhood Experiences (ACEs)
  • Behavioral Health
  • Community Health
  • Injury and Violence Prevention

Seeking LHD Participants for an Intersectional Data...

With support from the Centers for Disease Control and Prevention, NACCHO is...

Mar 28, 2024 | Camille Adams

Seeking LHD Participants for an Intersectional Data...

Ps24 posters d3 web

Day Three Highlights: 2024 Preparedness Summit

See highlights from day three of the 2024 Preparedness Summit.

Mar 27, 2024

Day Three Highlights: 2024 Preparedness Summit

D2 highlights web

Day Two Highlights: 2024 Preparedness Summit

See highlights from day two of the 2024 Preparedness Summit.

Mar 26, 2024

Day Two Highlights: 2024 Preparedness Summit

PS24 1

Day One Highlights: 2024 Preparedness Summit

See highlights from day one of the 2024 Preparedness Summit.

Mar 25, 2024

Day One Highlights: 2024 Preparedness Summit

PS24 web
  • Tools & Resources
  • Training

Welcome to the 2024 Preparedness Summit!

Welcome to the 2024 Preparedness Summit.

Mar 25, 2024 | Beth Hess

Welcome to the 2024 Preparedness Summit!

Stakeholder Conference Call on the FDA Integrated Food...

You’re invited to join the call on April 2 to hear more.

Mar 25, 2024

Stakeholder Conference Call on the FDA Integrated Food...

Cover and Spine for MAPP 2 0 Handbook Copy Page 1
  • Mobilizing for Action through Planning and Partnerships (MAPP)
  • Performance Improvement
  • Workforce Development

Register to Attend a Mobilizing for Action through...

Registration is now open for NACCHO’s in-person Mobilizing for Action through...

Mar 23, 2024 | Andrea Grenadier

Register to Attend a Mobilizing for Action through...

Capitol bulding

Congress Releases Labor-HHS Bill in Final FY2024 Package

Early on March 21st, Congress released the final minibus package for Fiscal...

Mar 22, 2024 | Victoria Van de Vate

Congress Releases Labor-HHS Bill in Final FY2024 Package

Back to Top